June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Prognostic factor of macular edema secondary to branch retinal vein occlusion treated with ranibizumab as needed dosing in Japanese patients.
Author Affiliations & Notes
  • Akira Ojima
    Ophthalmology, Fukushima Medical University, Fukushima, Japan
  • Tetsuju Sekiryu
    Ophthalmology, Fukushima Medical University, Fukushima, Japan
  • Hiroshi Oyamada
    Ophthalmology, Fukushima Medical University, Fukushima, Japan
  • Masashi Ogasawara
    Ophthalmology, Fukushima Medical University, Fukushima, Japan
  • Yasuharu Oguchi
    Ophthalmology, Fukushima Medical University, Fukushima, Japan
  • Footnotes
    Commercial Relationships Akira Ojima, None; Tetsuju Sekiryu, None; Hiroshi Oyamada, None; Masashi Ogasawara, None; Yasuharu Oguchi, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3744. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Akira Ojima, Tetsuju Sekiryu, Hiroshi Oyamada, Masashi Ogasawara, Yasuharu Oguchi; Prognostic factor of macular edema secondary to branch retinal vein occlusion treated with ranibizumab as needed dosing in Japanese patients.. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3744.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To identify predictive factors for visual outcome and frequency of injection in treating macular edema secondary to branch retinal vein occlusion (BRVO-ME) with ranibizumab in Japanese patients.

Methods: A retrospective case series. Forty one eyes of 41 patients with newly treated BRVO-ME were evaluated; 19 males and 22 females, mean age 70 years old. All patients underwent ophthalmic examination including measurement of the best corrected visual acuity (BCVA) and evaluation of the fovea using optical coherence tomography (OCT) (Cirrus OCT, Carl-Zeiss, Germany). All eyes were treated with intravitreal injection of ranibizumab (IVR) as the initial treatment and received as needed reinjection during 6 months followed-up period. Retreatment criteria was mean foveal thickness (MFT) was more than 250 µm or decreasing BCVA compared to that at the last visit.

Results: The mean number of IVR during 6 months was 3.4 times. The mean logMAR improved from 0.48 at baseline to 0.15 at 6 months (p<0.0001). The average of MFT decreased from 485.3±149.2μm at baseline to 285.2±64.2μm at 6 months (p<0.0001). The mean improvement in logMAR at month 6 correlated with the mean improvement in logMAR at month 1 (r=0.689, p<0.01). The mean improvement in MFT at month 6 correlated with the mean improvement in MFT at month 1 (r=0.843, p<0.01). The number of injection correlated with the average of MFT at baseline (r=0.378, p<0.02).

Conclusions: As needed dosing of ranibizumab was effective for BRVO-ME during 6 months. The mean improvements of logMAR and MFT at month 1 were useful as prognostic factors at month 6, respectively. Thicker MFT at baseline may need more frequent injections.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×